Formulación de Estrategias de Producción mas Limpia en la Industria Farmacéutica

Abstract

Like any investment, the decision to invest in cleaner production depends on the cost-benefit ratio. In practice, in the face of investment capital restrictions, the choice is made to adopt corrective environmental strategies (treatment at the end of the process), rather than preventive strategies, such as the case of cleaner production. however, when comparing the changes that are generated in the structure of total costs, when it is decided to invest in cleaner production and when not, it has that over time the costs decrease significantly, due to the benefits generated from the increase in the efficiency of the processes, the savings in the consumption of raw materials and energy, and the reduction of waste and polluting emissions. (Environment, 1997) The pharmaceutical industry has stood out in the area as a sector committed to environmental compliance and aware of the importance of caring for the environment, so it decides to participate in the RedesCAR program, identifying in this invitation an opportunity to strengthen its corporate environmental responsibility with the formulation of voluntary environmental programs that generate reputational and economic incentives. Through which the company assumes the challenge of evaluating its environmental performance and formulating new strategies for continuous improvement, productive transformation and reduction of its environmental impact.